Analysis of more than 2 million US surgical patients links pre-operative GLP-1 use with slightly lower rates of major cardiovascular complications and infections, though researchers stress the findings do not prove the drugs caused the benefit.
A large new analysis presented at the ANESTHESIOLOGY 2026 annual meeting suggests that patients taking GLP-1 medicines before surgery may be less likely to suffer serious heart-related complications or infections afterwards. The findings, based on more than 2 million adult surgical patients in the United States, add an unexpected twist to the debate over a class of drugs that has already drawn close scrutiny from anaesthesiologists because of its effect on stomach emptying. Newswise reported that the study included nearly 146,000 people using GLP-1 medicines, and the reported associations held after researchers matched them with similar patients who were not taking the drugs.
The work was led by Josephine Tolan, an anaesthesiologist at McGovern Medical School at UTHealth Houston, using Epic Cosmos, a database of de-identified electronic health records. The study focused on elective operations lasting more than an hour, with patients staying in hospital for at least 24 hours afterwards. In the matched comparison, major cardiovascular complications, including heart attack, stroke, cardiac injury and death, occurred in 1.0% of GLP-1 users and 1.1% of non-users. Post-operative infections were recorded in 4.9% and 5.3% respectively. Tolan said, “These results are encouraging, but we need more research to determine if the medications themselves are driving these benefits and how best to manage them before and after surgery.”
Even so, the results do not prove the drugs caused the better outcomes. Reuters-style caution is warranted because the patients were not randomly assigned to treatment, which means other differences may still have influenced the findings despite statistical adjustment. The researchers said one possible explanation is that GLP-1 medicines improve blood sugar, blood pressure and weight, while also reducing inflammation; better glucose control could also help lower infection risk. Jessica Duncan, an obesity-medicine physician and chief medical officer at Ivím Health, told Newsweek that “for an individual patient, that may be a small benefit, but across the millions of surgeries performed each year, it could be clinically relevant.”
The new research also sits alongside a separate body of evidence that has raised different questions about surgical safety. A study published in Annals of Surgery found that pre-operative GLP-1 receptor agonist use was not linked to worse outcomes in a cohort of 138,980 patients having major operations, while a separate UK analysis published in September examined regurgitation and aspiration, issues that matter to anaesthesiologists because they can occur when stomach contents enter the airway during anaesthesia. That British study found more regurgitation or aspiration events among GLP-1 users, but it did not show that the medicines caused those events, and only a small number involved actual aspiration. For now, the practical advice remains unchanged: patients should not alter their doses on their own, but should discuss timing with their surgeon, anaesthesiologist and prescribing clinician as guidance continues to evolve.
Disclaimer: This content is for informational purposes only and is not intended to be a substitute for professional medical judgment, advice, diagnosis, or treatment.
